TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00785941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 2~10 mg/kg I.V., once every other week for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 3~15 mg/kg I.V., once every other week for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 4~21 mg/kg I.V., once every other week for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 5~27 mg/kg I.V., once every other week for 4 weeks
Study: NCT05299450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet It shots
Description: In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet It shots
Description: In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
Study: NCT03553173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological advice
Description: Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
Study: NCT05299450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
Study: NCT01233167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: clopidogrel 75 mg po per day for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 75mg po per day for 12 months
Study: NCT03553173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Pill
Description: Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
Study: NCT01233167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel and placebo
Description: clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
Study: NCT03553173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Pill
Description: Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Pill
Description: Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Pill
Description: Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
Study: NCT03848819

Intervention type: DEVICE
Group type: OTHER
Intervention: VitaBreath device
Description: The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaBreath device
Description: The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
Study: NCT05448079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual counseling according to the PLISSIT model, randomized pretest-posttest
Description: experimental and control ,a randomized pretest-posttest study to examine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual counseling according to the PLISSIT model, randomized pretest-posttest
Description: experimental and control ,a randomized pretest-posttest study to examine
Study: NCT02363205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-administrated CBT-Treatment
Description: Guided internet-delivered CBT with chat sessions
Study: NCT01147783

Intervention type: OTHER
Intervention: CT, MRI

Intervention type: OTHER
Intervention: CT, MRI
Study: NCT01486264

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin®
Description: Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin®
Description: Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
Study: NCT02980614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4D flow imaging
Description: To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
Study: NCT01779609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise training program of 8 weeks, for 3x/week

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Supervised exercise training program of 8 weeks, for 3x/week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Supervised exercise training program of 8 weeks, for 3x/week
Study: NCT00367757

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablate AF triggers via PVI
Description: Trigger-based ablation guided by pulmonary vein antrum isolation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Substrate via CFAEs
Description: Substrate-based ablation using an approach targeting CFAEs

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Combined approach for AF ablation
Description: Combined trigger and substrate based approach
Study: NCT04281797

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal microbiome new generation sequencing
Description: Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal microbiome new generation sequencing
Description: Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal microbiome new generation sequencing
Description: Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal microbiome new generation sequencing
Description: Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
Study: NCT00800072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOWOX
Description: one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
Study: NCT00606515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel
Description: Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
Study: NCT02739087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI guided cardiac catheterization
Description: Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Study: NCT06563024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FET PET/CT
Description: The enrolled patients receive the 18F-FET PET/CT.
Study: NCT04350359

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variable-dose TTNS Protocol 5 x week
Description: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-dose TTNS Protocol
Description: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variable-dose TTNS Protocol 2 x week
Description: At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
Study: NCT01628835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dietary glycemic index diet
Description: Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National recommendation diet
Description: Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
Study: NCT01124175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 100 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozaar®
Description: 100 mg Tablets
Study: NCT01826058

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Study: NCT03916263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Traditional care including diet, exercise and metformin

Intervention type: OTHER
Group type: OTHER
Intervention: One-On-One Dietary Instruction
Description: Participant receives one-on-one dietary counseling from study personnel

Intervention type: OTHER
Group type: OTHER
Intervention: Video Dietary Instruction
Description: Participant receives video dietary instruction
Study: NCT02163837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximine
Study: NCT02269995

Intervention type: DEVICE
Intervention: E7040
Description: E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
Study: NCT01148030

Intervention type: DRUG
Intervention: 3M Skin and Nasal Antiseptic
Description: Intra-nasal dosing
Study: NCT02173834

Intervention type: OTHER
Group type: OTHER
Intervention: 18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan

Intervention type: OTHER
Group type: OTHER
Intervention: 18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan
Study: NCT01753375

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 given as 50000 IU orally on weekly basis

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be given orally on weekly basis
Study: NCT02356978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm1 homemade phototherapy treatment
Description: session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRAP
Study: NCT01163461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech therapy
Description: individuals will receive 60 hours of behavioral speech therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech therapy
Description: individuals will receive 60 hours of behavioral speech therapy
Study: NCT03772522

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: dk Leadership
Description: Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dk Leadership
Description: Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
Study: NCT05278507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrowga+rd Blue Advance Protection PICC Placement
Description: The PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator PICC placement
Description: The sham comparator PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
Study: NCT02956460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: contact lens
Study: NCT03734718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP
Description: Infusion of Glucose-dependent insulinotropic peptide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIP
Description: Infusion of Glucose-dependent insulinotropic peptide
Study: NCT05299450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
Study: NCT04656080

Intervention type: BEHAVIORAL
Intervention: CPET exercise testing
Description: * The cardiopulmonary exercise testing (CPET) is done.~* EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET.

Intervention type: BEHAVIORAL
Intervention: CPET exercise testing
Description: * The cardiopulmonary exercise testing (CPET) is done.~* EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET.
Study: NCT02378935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT02951273

Intervention type: OTHER
Intervention: Study of cerebral blood flow
Description: Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml.
Study: NCT01931865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
Study: NCT00835991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin 5 mg/500 mg Tablets
Description: 1 x 5 mg/500 mg, single-dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucovance® 5 mg/500 mg Tablets
Description: 1 x 5 mg/500 mg, single-dose fed